GSK will provide funding and certain milestone payments to Alnylam, as per the deal.
VaxiRNA is an RNAi technology for the enhanced production of viruses used in the manufacture of vaccine products.
The technology platform applies siRNAs for the silencing of specific genes that limit or prevent efficient growth of viruses in vaccine manufacturing systems, including those in cell culture and also in eggs.
The companies intend to focus initially on influenza vaccine production in cell culture systems.